Recent

% | $
Quotes you view appear here for quick access.

SAVİENT PHARM AŞ Message Board

  • kampaa_kampa kampaa_kampa Oct 3, 2013 11:27 PM Flag

    Abstract: #861 - Is one of the excellent news - Indicates a direct and large market potential

    That abstract was a very nice surprise. I did not see it, when I earlier searched and a week ago posted about the other abstracts. See my post "FIVE very GOOD pegloticase abstracts released today. ACR annual meeting 2013"

    This indicates IMO a VERY nice market and a VERY high number of potential patients - "The new ACR treatment guidelines recommend these patients should be considered for an increase in ULT dose or other treatment change, but no change was made in nearly 1/2 of encounters. " The results shows - "Among those on Higher Dose ULT, 50% had an SUA higher than 6 mg/dl"

    "Conclusion: Our results suggest that a high percentage of gout patients treated by rheumatologists are not at ACR recognized treatment goals, even after 6 months on Higher Dose ULT. The new ACR treatment guidelines recommend these patients should be considered for an increase in ULT dose or other treatment change, but no change was made in nearly 1/2 of encounters. These findings indicate gout management is currently suboptimal and inadequately aggressive for many patients. Further study is needed to determine the long-term impact of the new ACR treatment guidelines."

    In my opinion and no advice.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "Among those on Higher Dose ULT, 50% had an SUA higher than 6 mg/dl"

      How many patients in the total market? If 50% need a better treatment to go below 6 mg/d.

      KRYSTEXXA normalizes plasma uric acid levels1
      Statistically significant difference in proportion of patients who achieved PUA concentration of less than 6 mg/dL for at least 80% of the time during Months 3 and 6 vs placebo1

      Sentiment: Strong Buy

      • 1 Reply to kampaa_kampa
      • How good is KRYSTEXXA to normalize plasma uric acid levels?? Take that in consideration If 50% need a better treatment to go below 6 mg/d. This study was recently published in Arthritis Research & Therapy 2013, Publication date 26 September 2013. "Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy"

        From the results:
        "The rapid tophus resolution seen with pegloticase treatment may be explained by the profound and sustained lowering of urate. In vitro experiments have shown that the rate at which urate crystals dissolve is proportional to the degree of urate lowering in the surrounding fluid"

        From the conclusion:
        "Continued treatment with pegloticase resulted in progressively greater numbers of patients with a best overall tophus response of complete resolution. This proportion reached 59% of patients by their final visit in the OLE study among all patients who received pegloticase during both the RCT and OLE. Importantly, tophus CR was achieved by more than 80% of patients who maintained PUA less then 6 mg/dL for the duration of treatment."

        I like this: more than 80% of patients who maintained PUA less then 6 mg/dL!!

        Sentiment: Strong Buy

    • Kampa, this is a great opportunity for SAVIENT...

    • Read the study background. AND Remember this - "in Oct 2012, the ACR published guidelines for the management of gout." The study gives indication that there are gaps in current practice per the NEW (Oct 2012) ACR recommendations.

      "Background/Purpose: In Oct 2012, the ACR published guidelines for the management of gout. These guidelines recommend pharmacologic treatment that results in a sufficient lowering of the serum urate level to durably improve signs and symptoms of gout, including palpable and visible tophi, with a target of

      Sentiment: Strong Buy

      • 1 Reply to kampaa_kampa
      • "Background/Purpose: In Oct 2012, the ACR published guidelines for the management of gout. These guidelines recommend pharmacologic treatment that results in a sufficient lowering of the serum urate level to durably improve signs and symptoms of gout, including palpable and visible tophi, with a target of less 6 mg/dl at a minimum, and often less 5 mg/dl. (Khanna et al. Arthritis Care & Research 2012; 64 10:1431-46.) The extent to which current practice among rheumatologists aligns with these guidelines is unknown, and the areas in which the guidelines may help improve gout treatment remain to be determined. Our purpose was to assess symptoms, treatment, and outcomes among gout patients treated by US rheumatologists and identify any gaps in current practice per the new ACR recommendations."

        Sentiment: Strong Buy

    • There is a need for more effective, more efficient, more tolerable, and easier treatment for gout than the present treatments including Krystexxa. This is why other outfits are researching better treatments.

      Tell us nincompoop, why is this paper related to Krystexxa per se? Why does Savient mention it? Do the words Krystexxa, Pegloticase, Puricase appear in it? We have all known for years that Krystexxa is the best for treating tophi but the treatment has severe downsides detailed many times on this board.

      --Methods: We recruited a national sample of rheumatologists to report gout patient encounters prospectively between Jan 15 and Feb 22, 2013. Anonymous patient data collected included demographics, gout symptoms, rheumatologist assessment of control, gout medications and treatment changes. We applied the ACR working case “scenarios” used in the guideline process and grouped patients by increasing severity: ACR scenarios 1-3 (intermittent symptoms, no tophi), scenarios 4-6 (intermittent symptoms, ≥ 1 tophus) and scenarios 7-9 (Chronic Tophaceous Gouty Arthropathy). We defined “Higher Dose ULT” (Urate Lowering Therapy) as 300mg/day of allopurinol or ≥80 mg/day of febuxostat.----

      Savient presented multiple abstracts also for the 2012 ACR meeting. How well has Savient done since?

      • 2 Replies to c757172
      • c757, I haven't read or attempted to study any of the abstracts in detail yet. So, I cannot say with confidence just what they mean for SVNT's SP going forward. I think it's safe to say they are positive but just how much I'm not sure anyone can figure that out yet for sure. I think you might have a point that these studies do tend to point out that MDs are continuously wanting more effective, more efficient, more tolerable, and easier treatment for gout than the present treatments including Krystexxa". However, now and for the forseable future, 'K' is the most effective approved treatment for RCG worldwide. kg

      • c757172 seems to have a duty to post FUD and he work likely on the behalf of a short selling hedge fund. I know how this guy works - from his previous behavior regarding Vanda - and he was infamous at the VNDA message board.

        c757172 has a habit in misleading the reader - WITH - FUD Fear, Uncertainty, and Doubt. Check his history of subtle negative posts. You can not find any contributing information from him -- TRY. He bashed VNDA last fall when it was below $4 (trades today at $11) - NOW in the same style with SVNT.

        I would never trust him.

        c757172 --
        Is this kind of post you refer to?? - when you bought VNDA at $3 and said "Just do not forget to sell on a 15 cents rebound." And this kind of Tasimelteon believe from you: "Assuming worse-case scenario that by mid-2013, the Tas trials come short and Vanda liquidates." There is no rush to the door but it appears that the market thinks that Tas will amount to nothing profitable" (c757172 • Nov 8, 2012 12:18 PM )

        "Reply to 3.20 in chart by kampaa_kampa •Nov 8, 2012 11:29 AM
        c757172 • Nov 8, 2012 11:42 AM Flag
        0users liked this postsusers disliked this posts0Reply
        Yes, it is a buy now. Dropped below the cash a year hence. Just do not forget to sell on a 15 cents rebound."

        Do not be fooled by a basher.
        DO YOUR own DD.

        In my opinion.

        Sentiment: Strong Buy

    • Kampa, I AGREE with you, Thank you for your GREAT MESSAGE.

    • Your "opinion" as you state is jaded and unrealistic. Also your opinion has no merit or credulity to anyone on this board. Care to explain why and how any of this is important, relevant, or dynamic for Savient? You are acting and cheerleading as if abstracts carry some large value. Sorry bet they dont. None of this can be promoted or shared, none of these are approved field and sales pieces. None of these abstracts carry any significant bearing and on top of that, Savient has no share of voice or sales team. They could have shown that K cures polio and it still is irrelevant as Savient has no commercial infratstruce after the lay offs and termination's of their sales team. You sound like a insecure desperate clown. is approved sales or marketing

    • AND this abstract is the ONLY one to be presented as "Oral" - gives a nice impact.
      I recommend you to read it.

      Many Gout Patients Treated By Rheumatologists Do Not Meet Established Treatment Goals Despite Long-Term Urate Lowering Therapy: Results Of a Gout Patient Encounter Survey; Abstract #861 (Oral); Sunday, October 27, 2013, 5:45pm PT

      In my opinion and no advice

      Sentiment: Strong Buy

 
SVNTQ
0.00(0.00%)